nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—ABCB1—ovarian cancer	0.242	1	CbGaD
Cyclophosphamide—CYP3A7—Paclitaxel—ovarian cancer	0.0373	0.0845	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0373	0.0845	CbGbCtD
Cyclophosphamide—ABCB1—Topotecan—ovarian cancer	0.0368	0.0833	CbGbCtD
Cyclophosphamide—CYP3A5—Paclitaxel—ovarian cancer	0.028	0.0634	CbGbCtD
Cyclophosphamide—CYP3A7—Docetaxel—ovarian cancer	0.027	0.0611	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.027	0.0611	CbGbCtD
Cyclophosphamide—CYP2C8—Paclitaxel—ovarian cancer	0.0269	0.061	CbGbCtD
Cyclophosphamide—ABCB1—Vinorelbine—ovarian cancer	0.0259	0.0587	CbGbCtD
Cyclophosphamide—CYP2D6—Vinorelbine—ovarian cancer	0.0244	0.0553	CbGbCtD
Cyclophosphamide—CYP3A4—Topotecan—ovarian cancer	0.022	0.0499	CbGbCtD
Cyclophosphamide—CYP3A5—Docetaxel—ovarian cancer	0.0202	0.0458	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—ovarian cancer	0.0191	0.0434	CbGbCtD
Cyclophosphamide—CYP2C9—Paclitaxel—ovarian cancer	0.0188	0.0425	CbGbCtD
Cyclophosphamide—ABCB1—Paclitaxel—ovarian cancer	0.0182	0.0413	CbGbCtD
Cyclophosphamide—CYP3A4—Vinorelbine—ovarian cancer	0.0155	0.0352	CbGbCtD
Cyclophosphamide—ABCB1—Docetaxel—ovarian cancer	0.0132	0.0298	CbGbCtD
Cyclophosphamide—CYP3A4—Paclitaxel—ovarian cancer	0.0109	0.0247	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—ovarian cancer	0.00982	0.0222	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—ovarian cancer	0.00925	0.021	CbGbCtD
Cyclophosphamide—CYP3A4—Docetaxel—ovarian cancer	0.00789	0.0179	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—ovarian cancer	0.00588	0.0133	CbGbCtD
Cyclophosphamide—Dermatitis—Topotecan—ovarian cancer	9.97e-05	0.000315	CcSEcCtD
Cyclophosphamide—Headache—Topotecan—ovarian cancer	9.92e-05	0.000313	CcSEcCtD
Cyclophosphamide—Palpitations—Paclitaxel—ovarian cancer	9.86e-05	0.000311	CcSEcCtD
Cyclophosphamide—Vomiting—Melphalan—ovarian cancer	9.86e-05	0.000311	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—ovarian cancer	9.84e-05	0.000311	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	9.8e-05	0.000309	CcSEcCtD
Cyclophosphamide—Rash—Melphalan—ovarian cancer	9.77e-05	0.000308	CcSEcCtD
Cyclophosphamide—Dermatitis—Melphalan—ovarian cancer	9.76e-05	0.000308	CcSEcCtD
Cyclophosphamide—Chills—Docetaxel—ovarian cancer	9.75e-05	0.000308	CcSEcCtD
Cyclophosphamide—Cough—Paclitaxel—ovarian cancer	9.74e-05	0.000307	CcSEcCtD
Cyclophosphamide—Asthenia—Vinorelbine—ovarian cancer	9.72e-05	0.000307	CcSEcCtD
Cyclophosphamide—Arrhythmia—Docetaxel—ovarian cancer	9.71e-05	0.000306	CcSEcCtD
Cyclophosphamide—Convulsion—Paclitaxel—ovarian cancer	9.67e-05	0.000305	CcSEcCtD
Cyclophosphamide—Hypertension—Paclitaxel—ovarian cancer	9.64e-05	0.000304	CcSEcCtD
Cyclophosphamide—Alopecia—Docetaxel—ovarian cancer	9.6e-05	0.000303	CcSEcCtD
Cyclophosphamide—Pruritus—Vinorelbine—ovarian cancer	9.58e-05	0.000302	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	9.54e-05	0.000301	CcSEcCtD
Cyclophosphamide—Chest pain—Paclitaxel—ovarian cancer	9.5e-05	0.0003	CcSEcCtD
Cyclophosphamide—Arthralgia—Paclitaxel—ovarian cancer	9.5e-05	0.0003	CcSEcCtD
Cyclophosphamide—Myalgia—Paclitaxel—ovarian cancer	9.5e-05	0.0003	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—ovarian cancer	9.47e-05	0.000299	CcSEcCtD
Cyclophosphamide—Erythema—Docetaxel—ovarian cancer	9.46e-05	0.000298	CcSEcCtD
Cyclophosphamide—Nausea—Topotecan—ovarian cancer	9.4e-05	0.000297	CcSEcCtD
Cyclophosphamide—Discomfort—Paclitaxel—ovarian cancer	9.39e-05	0.000296	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—ovarian cancer	9.32e-05	0.000294	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vinorelbine—ovarian cancer	9.27e-05	0.000292	CcSEcCtD
Cyclophosphamide—Dysgeusia—Docetaxel—ovarian cancer	9.26e-05	0.000292	CcSEcCtD
Cyclophosphamide—Nausea—Melphalan—ovarian cancer	9.21e-05	0.00029	CcSEcCtD
Cyclophosphamide—Confusional state—Paclitaxel—ovarian cancer	9.18e-05	0.00029	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Paclitaxel—ovarian cancer	9.11e-05	0.000287	CcSEcCtD
Cyclophosphamide—Oedema—Paclitaxel—ovarian cancer	9.11e-05	0.000287	CcSEcCtD
Cyclophosphamide—Muscle spasms—Docetaxel—ovarian cancer	9.1e-05	0.000287	CcSEcCtD
Cyclophosphamide—Infection—Paclitaxel—ovarian cancer	9.05e-05	0.000285	CcSEcCtD
Cyclophosphamide—Shock—Paclitaxel—ovarian cancer	8.96e-05	0.000283	CcSEcCtD
Cyclophosphamide—Dizziness—Vinorelbine—ovarian cancer	8.96e-05	0.000283	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Paclitaxel—ovarian cancer	8.92e-05	0.000281	CcSEcCtD
Cyclophosphamide—Tachycardia—Paclitaxel—ovarian cancer	8.89e-05	0.00028	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	8.83e-05	0.000279	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Paclitaxel—ovarian cancer	8.81e-05	0.000278	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—ovarian cancer	8.77e-05	0.000277	CcSEcCtD
Cyclophosphamide—Anaemia—Docetaxel—ovarian cancer	8.74e-05	0.000276	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—ovarian cancer	8.7e-05	0.000274	CcSEcCtD
Cyclophosphamide—Anorexia—Paclitaxel—ovarian cancer	8.68e-05	0.000274	CcSEcCtD
Cyclophosphamide—Vomiting—Vinorelbine—ovarian cancer	8.61e-05	0.000272	CcSEcCtD
Cyclophosphamide—Rash—Vinorelbine—ovarian cancer	8.54e-05	0.000269	CcSEcCtD
Cyclophosphamide—Dermatitis—Vinorelbine—ovarian cancer	8.53e-05	0.000269	CcSEcCtD
Cyclophosphamide—Hypotension—Paclitaxel—ovarian cancer	8.51e-05	0.000269	CcSEcCtD
Cyclophosphamide—Headache—Vinorelbine—ovarian cancer	8.48e-05	0.000268	CcSEcCtD
Cyclophosphamide—Leukopenia—Docetaxel—ovarian cancer	8.47e-05	0.000267	CcSEcCtD
Cyclophosphamide—Palpitations—Docetaxel—ovarian cancer	8.36e-05	0.000264	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—ovarian cancer	8.33e-05	0.000263	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	8.3e-05	0.000262	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—ovarian cancer	8.26e-05	0.000261	CcSEcCtD
Cyclophosphamide—Cough—Docetaxel—ovarian cancer	8.26e-05	0.00026	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—ovarian cancer	8.21e-05	0.000259	CcSEcCtD
Cyclophosphamide—Convulsion—Docetaxel—ovarian cancer	8.2e-05	0.000259	CcSEcCtD
Cyclophosphamide—Paraesthesia—Paclitaxel—ovarian cancer	8.18e-05	0.000258	CcSEcCtD
Cyclophosphamide—Hypertension—Docetaxel—ovarian cancer	8.17e-05	0.000258	CcSEcCtD
Cyclophosphamide—Dyspnoea—Paclitaxel—ovarian cancer	8.12e-05	0.000256	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	8.1e-05	0.000255	CcSEcCtD
Cyclophosphamide—Arthralgia—Docetaxel—ovarian cancer	8.05e-05	0.000254	CcSEcCtD
Cyclophosphamide—Myalgia—Docetaxel—ovarian cancer	8.05e-05	0.000254	CcSEcCtD
Cyclophosphamide—Chest pain—Docetaxel—ovarian cancer	8.05e-05	0.000254	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—ovarian cancer	8.05e-05	0.000254	CcSEcCtD
Cyclophosphamide—Nausea—Vinorelbine—ovarian cancer	8.04e-05	0.000254	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—ovarian cancer	8.03e-05	0.000253	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—ovarian cancer	8e-05	0.000253	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—ovarian cancer	7.96e-05	0.000251	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—ovarian cancer	7.96e-05	0.000251	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—ovarian cancer	7.94e-05	0.00025	CcSEcCtD
Cyclophosphamide—Decreased appetite—Paclitaxel—ovarian cancer	7.92e-05	0.00025	CcSEcCtD
Cyclophosphamide—Fatigue—Paclitaxel—ovarian cancer	7.85e-05	0.000248	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—ovarian cancer	7.83e-05	0.000247	CcSEcCtD
Cyclophosphamide—Pain—Paclitaxel—ovarian cancer	7.79e-05	0.000246	CcSEcCtD
Cyclophosphamide—Constipation—Paclitaxel—ovarian cancer	7.79e-05	0.000246	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—ovarian cancer	7.79e-05	0.000246	CcSEcCtD
Cyclophosphamide—Confusional state—Docetaxel—ovarian cancer	7.79e-05	0.000246	CcSEcCtD
Cyclophosphamide—Oedema—Docetaxel—ovarian cancer	7.72e-05	0.000244	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Docetaxel—ovarian cancer	7.72e-05	0.000244	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—ovarian cancer	7.71e-05	0.000243	CcSEcCtD
Cyclophosphamide—Infection—Docetaxel—ovarian cancer	7.67e-05	0.000242	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—ovarian cancer	7.64e-05	0.000241	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—ovarian cancer	7.62e-05	0.00024	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—ovarian cancer	7.6e-05	0.00024	CcSEcCtD
Cyclophosphamide—Shock—Docetaxel—ovarian cancer	7.6e-05	0.00024	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Docetaxel—ovarian cancer	7.56e-05	0.000238	CcSEcCtD
Cyclophosphamide—Tachycardia—Docetaxel—ovarian cancer	7.54e-05	0.000238	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Paclitaxel—ovarian cancer	7.51e-05	0.000237	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.49e-05	0.000236	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—ovarian cancer	7.46e-05	0.000235	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—ovarian cancer	7.43e-05	0.000234	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.41e-05	0.000234	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—ovarian cancer	7.37e-05	0.000232	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—ovarian cancer	7.36e-05	0.000232	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—ovarian cancer	7.36e-05	0.000232	CcSEcCtD
Cyclophosphamide—Anorexia—Docetaxel—ovarian cancer	7.36e-05	0.000232	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—ovarian cancer	7.35e-05	0.000232	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—ovarian cancer	7.34e-05	0.000232	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—ovarian cancer	7.33e-05	0.000231	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—ovarian cancer	7.33e-05	0.000231	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—ovarian cancer	7.29e-05	0.00023	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—ovarian cancer	7.24e-05	0.000229	CcSEcCtD
Cyclophosphamide—Urticaria—Paclitaxel—ovarian cancer	7.24e-05	0.000228	CcSEcCtD
Cyclophosphamide—Hypotension—Docetaxel—ovarian cancer	7.21e-05	0.000228	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—ovarian cancer	7.2e-05	0.000227	CcSEcCtD
Cyclophosphamide—Body temperature increased—Paclitaxel—ovarian cancer	7.2e-05	0.000227	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—ovarian cancer	7.06e-05	0.000223	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—ovarian cancer	7.05e-05	0.000222	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.03e-05	0.000222	CcSEcCtD
Cyclophosphamide—Paraesthesia—Docetaxel—ovarian cancer	6.93e-05	0.000219	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—ovarian cancer	6.93e-05	0.000219	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—ovarian cancer	6.9e-05	0.000218	CcSEcCtD
Cyclophosphamide—Dyspnoea—Docetaxel—ovarian cancer	6.88e-05	0.000217	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—ovarian cancer	6.83e-05	0.000216	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—ovarian cancer	6.82e-05	0.000215	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—ovarian cancer	6.8e-05	0.000215	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—ovarian cancer	6.8e-05	0.000215	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—ovarian cancer	6.78e-05	0.000214	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—ovarian cancer	6.78e-05	0.000214	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—ovarian cancer	6.75e-05	0.000213	CcSEcCtD
Cyclophosphamide—Decreased appetite—Docetaxel—ovarian cancer	6.71e-05	0.000212	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Paclitaxel—ovarian cancer	6.71e-05	0.000212	CcSEcCtD
Cyclophosphamide—Fatigue—Docetaxel—ovarian cancer	6.66e-05	0.00021	CcSEcCtD
Cyclophosphamide—Pain—Docetaxel—ovarian cancer	6.6e-05	0.000208	CcSEcCtD
Cyclophosphamide—Constipation—Docetaxel—ovarian cancer	6.6e-05	0.000208	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—ovarian cancer	6.58e-05	0.000207	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—ovarian cancer	6.55e-05	0.000207	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—ovarian cancer	6.54e-05	0.000206	CcSEcCtD
Cyclophosphamide—Asthenia—Paclitaxel—ovarian cancer	6.54e-05	0.000206	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—ovarian cancer	6.48e-05	0.000204	CcSEcCtD
Cyclophosphamide—Pruritus—Paclitaxel—ovarian cancer	6.44e-05	0.000203	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—ovarian cancer	6.41e-05	0.000202	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—ovarian cancer	6.38e-05	0.000201	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Docetaxel—ovarian cancer	6.36e-05	0.000201	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—ovarian cancer	6.32e-05	0.000199	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—ovarian cancer	6.29e-05	0.000199	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—ovarian cancer	6.25e-05	0.000197	CcSEcCtD
Cyclophosphamide—Diarrhoea—Paclitaxel—ovarian cancer	6.23e-05	0.000197	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—ovarian cancer	6.13e-05	0.000194	CcSEcCtD
Cyclophosphamide—Body temperature increased—Docetaxel—ovarian cancer	6.1e-05	0.000193	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—ovarian cancer	6.09e-05	0.000192	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—ovarian cancer	6.06e-05	0.000191	CcSEcCtD
Cyclophosphamide—Dizziness—Paclitaxel—ovarian cancer	6.02e-05	0.00019	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—ovarian cancer	6.01e-05	0.00019	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—ovarian cancer	5.99e-05	0.000189	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—ovarian cancer	5.92e-05	0.000187	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—ovarian cancer	5.9e-05	0.000186	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—ovarian cancer	5.9e-05	0.000186	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—ovarian cancer	5.86e-05	0.000185	CcSEcCtD
Cyclophosphamide—Vomiting—Paclitaxel—ovarian cancer	5.79e-05	0.000183	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—ovarian cancer	5.78e-05	0.000182	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—ovarian cancer	5.75e-05	0.000182	CcSEcCtD
Cyclophosphamide—Rash—Paclitaxel—ovarian cancer	5.74e-05	0.000181	CcSEcCtD
Cyclophosphamide—Dermatitis—Paclitaxel—ovarian cancer	5.74e-05	0.000181	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—ovarian cancer	5.71e-05	0.00018	CcSEcCtD
Cyclophosphamide—Headache—Paclitaxel—ovarian cancer	5.71e-05	0.00018	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Docetaxel—ovarian cancer	5.69e-05	0.000179	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—ovarian cancer	5.68e-05	0.000179	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—ovarian cancer	5.64e-05	0.000178	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—ovarian cancer	5.57e-05	0.000176	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—ovarian cancer	5.56e-05	0.000176	CcSEcCtD
Cyclophosphamide—Asthenia—Docetaxel—ovarian cancer	5.54e-05	0.000175	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—ovarian cancer	5.53e-05	0.000174	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—ovarian cancer	5.51e-05	0.000174	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—ovarian cancer	5.48e-05	0.000173	CcSEcCtD
Cyclophosphamide—Pruritus—Docetaxel—ovarian cancer	5.46e-05	0.000172	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—ovarian cancer	5.46e-05	0.000172	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—ovarian cancer	5.43e-05	0.000171	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—ovarian cancer	5.43e-05	0.000171	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—ovarian cancer	5.43e-05	0.000171	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—ovarian cancer	5.43e-05	0.000171	CcSEcCtD
Cyclophosphamide—Nausea—Paclitaxel—ovarian cancer	5.41e-05	0.000171	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—ovarian cancer	5.37e-05	0.000169	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—ovarian cancer	5.32e-05	0.000168	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—ovarian cancer	5.28e-05	0.000167	CcSEcCtD
Cyclophosphamide—Diarrhoea—Docetaxel—ovarian cancer	5.28e-05	0.000167	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—ovarian cancer	5.25e-05	0.000166	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—ovarian cancer	5.22e-05	0.000165	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—ovarian cancer	5.21e-05	0.000164	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—ovarian cancer	5.21e-05	0.000164	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—ovarian cancer	5.17e-05	0.000163	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—ovarian cancer	5.15e-05	0.000163	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—ovarian cancer	5.12e-05	0.000162	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—ovarian cancer	5.12e-05	0.000161	CcSEcCtD
Cyclophosphamide—Dizziness—Docetaxel—ovarian cancer	5.11e-05	0.000161	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—ovarian cancer	5.1e-05	0.000161	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—ovarian cancer	5.1e-05	0.000161	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—ovarian cancer	5.08e-05	0.00016	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—ovarian cancer	5.03e-05	0.000159	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—ovarian cancer	5.03e-05	0.000159	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—ovarian cancer	5.03e-05	0.000159	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—ovarian cancer	5.03e-05	0.000159	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—ovarian cancer	4.97e-05	0.000157	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—ovarian cancer	4.96e-05	0.000157	CcSEcCtD
Cyclophosphamide—Vomiting—Docetaxel—ovarian cancer	4.91e-05	0.000155	CcSEcCtD
Cyclophosphamide—Rash—Docetaxel—ovarian cancer	4.87e-05	0.000154	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—ovarian cancer	4.87e-05	0.000154	CcSEcCtD
Cyclophosphamide—Dermatitis—Docetaxel—ovarian cancer	4.86e-05	0.000153	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—ovarian cancer	4.86e-05	0.000153	CcSEcCtD
Cyclophosphamide—Headache—Docetaxel—ovarian cancer	4.84e-05	0.000153	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—ovarian cancer	4.82e-05	0.000152	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—ovarian cancer	4.82e-05	0.000152	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—ovarian cancer	4.79e-05	0.000151	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.74e-05	0.00015	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—ovarian cancer	4.74e-05	0.00015	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—ovarian cancer	4.72e-05	0.000149	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—ovarian cancer	4.7e-05	0.000148	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—ovarian cancer	4.68e-05	0.000148	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—ovarian cancer	4.66e-05	0.000147	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—ovarian cancer	4.64e-05	0.000146	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—ovarian cancer	4.59e-05	0.000145	CcSEcCtD
Cyclophosphamide—Nausea—Docetaxel—ovarian cancer	4.59e-05	0.000145	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—ovarian cancer	4.53e-05	0.000143	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—ovarian cancer	4.5e-05	0.000142	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—ovarian cancer	4.49e-05	0.000142	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—ovarian cancer	4.45e-05	0.00014	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—ovarian cancer	4.45e-05	0.00014	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.39e-05	0.000138	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—ovarian cancer	4.33e-05	0.000137	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—ovarian cancer	4.3e-05	0.000136	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—ovarian cancer	4.29e-05	0.000135	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—ovarian cancer	4.19e-05	0.000132	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—ovarian cancer	4.15e-05	0.000131	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—ovarian cancer	4.14e-05	0.000131	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—ovarian cancer	4.12e-05	0.00013	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—ovarian cancer	4.12e-05	0.00013	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—ovarian cancer	4.12e-05	0.00013	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—ovarian cancer	3.97e-05	0.000125	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—ovarian cancer	3.84e-05	0.000121	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—ovarian cancer	3.83e-05	0.000121	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—ovarian cancer	3.81e-05	0.00012	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—ovarian cancer	3.74e-05	0.000118	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—ovarian cancer	3.68e-05	0.000116	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—ovarian cancer	3.56e-05	0.000112	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—ovarian cancer	3.55e-05	0.000112	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—ovarian cancer	3.46e-05	0.000109	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—ovarian cancer	3.44e-05	0.000109	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—ovarian cancer	3.41e-05	0.000108	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—ovarian cancer	3.31e-05	0.000104	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—ovarian cancer	3.3e-05	0.000104	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—ovarian cancer	3.28e-05	0.000104	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—ovarian cancer	3.28e-05	0.000103	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—ovarian cancer	3.26e-05	0.000103	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—ovarian cancer	3.19e-05	0.000101	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—ovarian cancer	3.09e-05	9.76e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—ovarian cancer	3.06e-05	9.67e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—ovarian cancer	3.04e-05	9.58e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—ovarian cancer	3.04e-05	9.58e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—ovarian cancer	3.02e-05	9.52e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—ovarian cancer	2.86e-05	9.03e-05	CcSEcCtD
